ClinicalTrials.gg
RecruitingNCT05306041GeparPiPPaUpdated Sep 11, 2026

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

A Phase 2 interventional study of Inavolisib and PHESGO in HER2-positive Breast Cancer, sponsored by GBG Forschungs GmbH. Recruiting at 62 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by GBG Forschungs GmbH · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing inavolisib in Breast Neoplasms — 12 open to participants now, 15 under way, 4 of them phase 3. inavolisib · Breast Neoplasms.

Planned enrollment
9th of 16
170 · median 185
Started
2023
with 3 others
Phase 2
10 of 16
8 open now
Primary completion
2027-01
later than 4 of 14 live
Registered
5th of 16
by date
Lead sponsor
1 of 16
GBG Forschungs GmbH

Among the 16 studies testing inavolisib in Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 4 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 5th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 16 studies testing inavolisib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About inavolisib

inavolisib: first FDA approval 2024 (ITOVEBI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inavolisib in Breast Neoplasms, or all of them as a file.
02

Study summary

Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.

Read the detailed description

This is a multicenter, prospective, randomized, open-label, parallel-group, phase II study to evaluate the potential incremental efficacy and safety of inavolisib in the neoadjuvant treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.

170 patients with confirmed eligibility criteria and PIK3CA mutant breast cancer will be randomized in a 1:1 ratio to receive: Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks) with (6cycles) or without inavolisib. Endocrine therapy consists of either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men.

In both study arms, treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient.

All patients will undergo surgery or biopsy after completing study therapy to assess pCR rate.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • GeparPiPPa
  • German Breast Group
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
  2. Untreated, unilateral primary carcinoma of the breast, confirmed histologically by core . Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed.
  3. Tumor lesion in the breast must be measurable in two dimensions, preferably by sonography.
  4. Patients must be in the following stages of disease:

    • cT1b - cT3 regardless of nodal status In patients with multifocal or multicentric breast cancer the largest lesion (target lesion) should be measured.
  5. HR+/+ disease with centrally confirmed ER-status, PR-status, HER2-status, PIK3CA mutation (tumor), Ki-67 value and TILs on core biopsy (target lesion). ER/PgR positive and HER2-positive is defined according to current ASCO/CAP guidelines. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy of target lesion has therefore to be sent to the GBG central pathology laboratory prior to randomization. In patients with multifocal or multicentric breast cancer, all non-target lesions must also be HR+/HER2+, as confirmed by local testing.
  6. Age ≥ 18 years, female and male.
  7. Performance status 0-1.
  8. Normal cardiac function must be confirmed by and cardiac ultrasound ( or shortening fraction) within 3 months prior to randomization. Results for LVEF must be above 55%.
  9. Laboratory requirements:

    Hematology

    • (ANC) ≥ 1.5/ nL
    • ≥ 100/ nL and
    • ≥ 10 g/dL (≥ 6.2 mmol/L) Hepatic function
    • Total \< except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN
    • and ALT ≤ 1.5x ULN and
    • Alkaline phosphatase ≤ 2.5x ULN

    Glucose Metabolism:

    • Glycosylated hemoglobin () \< 6.5%
  10. Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of . A woman is considered to be of childbearing potential if she is not hysterectomized or not .

    Postmenopausal is defined as:

    • ≥12 continuous months of amenorrhea with no identified cause other than menopause.
    • Having undergone bilateral oophorectomy.
  11. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \< 1% per year during the treatment period and for least 7 months after the last dose of PH-FDC SC. Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices. For men: men must remain abstinent or use a condom with a spermicidal product during the treatment period and for 7 months after the last dose of PH-FDC therapy to avoid exposing the embryo. Men and women must refrain from donating sperm/eggs during this same period.
  12. Staging work-up according to country guidelines prior to randomization including:

    • Bilateral mammography and/or breast MRI in combination with a breast ultrasound. Exception: In men where MRI is medically not indicated breast ultrasound is sufficient.
  13. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria

  1. Patients with -negative breast cancer and/or HER2-positive, HR-negative breast cancer.
  2. Need of immediate chemotherapy, e.g. inflammatory breast cancer.
  3. Patients with definitive clinical or radiologic evidence of Stage IV cancer.
  4. Excisional or lumpectomy and /or axillary lymph node dissection and/or sentinel lymph node biopsy performed prior to study entry (biopsy of clinical involved LN is warranted).
  5. Prior chemotherapy or endocrine therapy or radiation therapy prior to study entry with the following exceptions:

    • If medically indicated, initiation of endocrine therapy up to 28 days prior to randomization and use of established fertility preservation methods in young patients interested in subsequent pregnancies is allowed.
  6. Patients with a history of breast cancer are ineligible with the following exceptions:

    • Patient has been disease-free for more than 5 years and is at low risk for recurrence (at the investigator's discretion).
  7. Patients with a history of any treated are ineligible in case of high risk of recurrence (at the investigator's discretion) and/or ongoing oncological treatment. This also applies to patients who are at high risk that oncological treatment is indicated during study therapy.
  8. Patients with >30 can be included at the investigator's discretion.
  9. Known reaction to one of the compounds or substances, and/or murine proteins, and/or recombinant human hyaluronidase used in this protocol.
  10. Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II based on FPG and .
  11. Patients who are as the result of or receiving immunosuppressive therapies.
  12. and active liver disease, for example, sclerosing cholangitis, active viral or C infection, or hepatic disorders.
  13. Patients with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, and active bowel inflammation (e.g., diverticulitis).
  14. Patients with any concurrent ocular or intraocular condition, excluding baseline cataracts, that would require medical or surgical intervention during the study period to prevent or treat vision loss. In addition, patients with active uveitis or vitritis, history of uveitis, or active infectious process in the eye.
  15. Patients with currently documented pneumonitis/interstitial lung disease.
  16. Known or suspected congestive heart failure (> I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on , uncontrolled or poorly controlled arterial hypertension (i.e. BP >160 / 90 mm Hg under treatment with three antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
  17. Damaged skin at planned site of subcutaneous (SC) injections (thigh).
  18. Patients who may have had a recent episode of thromboembolism and are still trying to optimize the anticoagulation dose and/or have not normalized their .
  19. Concurrent treatment with: • Chronic unless initiated > 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent).

    • Sex hormones. Prior treatment must be stopped before randomization (GnRH a is allowed).
    • Other experimental drugs or any other anti-cancer therapy.
  20. Participation in another clinical trial with any , not marketed drug within 30 days prior to study entry.
  21. Female patients: pregnancy or lactation at the time of randomization.
  22. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of .
  23. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Inavolisib

    Inavolisib for 6 cycles (18 weeks) Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)

    Drug: Inavolisib · Drug: PHESGO · Drug: Endocrine therapy

  • Other
    without Inavolisib

    Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)

    Drug: PHESGO · Drug: Endocrine therapy

Interventions

  • daily application of 9 mg (may be decreased to 6 mg and to 3 mg)

  • DrugPertuzumab/Trastuzumab/Hyaluronidase-zzxfStudies of Pertuzumab/Trastuzumab/Hyaluronidase-zzxfPertuzumab/Trastuzumab/Hyaluronidase-zzxf pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)

  • DrugEndocrine therapy

    Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathologic complete response in the breast and axillary lymph nodes (ypT0/is ypN0)

    Pathological complete response (ypT0/is ypN0) is defined as no microscopic evidence of residual invasive tumor cells in all resected specimens of the breast and axilla.

    Time frame: 21 weeks (time window + 3 weeks)

Secondary outcomes

  1. Rates of ypT0 ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0

    ypT0 ypN0 is defined as no microscopic evidence of residual invasive or non-invasive viable tumor cells in all resected specimens of the breast and axilla; ypT0 ypN0/+ is defined as no microscopic evidence of residual invasive or non-invasive viable tumor cells in all resected specimens of the breast; ypT0/Tis ypN0/+ is defined as no microscopic evidence of residual invasive viable tumor cells in all resected specimens of the breast

    Time frame: 21 weeks (time window + 3 weeks)

  2. pCR rates per arm separately for the stratified subpopulations

    Pathological complete response (ypT0/is ypN0) is defined as no microscopic evidence of residual invasive tumor cells in all resected specimens of the breast and axilla.

    Time frame: 21 weeks (time window + 3 weeks)

  3. Response rates of the breast tumor and axillary nodes based on physical examination and imaging tests (sonography, mammography, or MRI) after study treatment in both arms

    Clinical (c) and imaging (i) response will be assessed every 2nd cycle and before surgery by physical examination and imaging tests. Sonography is the preferred examination. The response categories of the breast are: * Complete response (CR): complete disappearance of all tumor signs in the breast * Partial response (PR): reduction in the product of the two largest perpendicular diameters of the primary tumor size by 50% or more * Stable disease (NC): no significant change in tumor size during treatment which means an estimated reduction of the tumor area by less than 50%, or an estimated increase in the size of the tumor area lesions of less than 25% * Progressive disease (PD): development of new, previously undetected lesions, or an estimated increase in the size of pre-existing lesions by 25% or more after at least two cycles of therapy

    Time frame: 21 weeks (time window + 3 weeks)

  4. Percentage of patients receiving additional neoadjuvant chemotherapy after residual disease was confirmed by core biopsy at the end of study treatment

    In case of ycT0 and no tumor residuals in the biopsy, it is recommended to undergo surgery. Further neoadjuvant or adjuvant treatment including chemotherapy, radiotherapy, endocrine therapy and HER2-therapy will be administered at the discretion of the investigator and according to standard of care.

    Time frame: 21 weeks (time window + 3 weeks)

  5. Breast conservation rate after treatment

    Breast conservation is defined as tumorectomy, segmentectomy or quadrantectomy as a most radical surgery.

    Time frame: 21 weeks (time window + 3 weeks)

  6. Safety and tolerability profile (haematological and non-haematological adverse events) after the first 20 and the first 40 patients who started therapy and have completed two cycles of therapy

    Tolerability and safety analyses include assessment of patients whose treatment had to be dose reduced, delayed or permanently stopped. The reason for treatment discontinuation includes aspects of efficacy (e.g. discontinuation due to tumor progression), safety (e.g. discontinuation due to haematological and non-haematological adverse events) and compliance (e.g. discontinuation due to withdrawal of consent). Safety by toxicity grades are defined by the NCI-CTCAE version 5.0

    Time frame: 6 weeks

  7. Overall safety and tolerability and treatment compliance in the two arms

    Descriptive statistics for the 2 treatment arms will be given on the number of patients whose treatment had to be dose reduced, delayed or permanently stopped. Reasons for premature discontinuation will be categorized according to the main reason and will be presented in frequency tables. Safety by toxicity grades are defined by the NCI-CTCAE version 5.0, laboratory parameters will be converted in CTC-grades and reported together with other adverse events.

    Time frame: 21 weeks (time window + 3 weeks)

  8. Invasive disease-free survival (IDFS) and overall survival (OS) in both arms and according to stratified subpopulations (data collected within a registry).

    Survival endpoints are defined as the time period between randomization and first event and will be analyzed after the end of the study by referring to data from GBG´s registries

    Time frame: up to 5 years

07

Study locations

53 of 62 sites recruiting
  • KEM Kliniken Essen-Mitte
    Essen, North Rhine-Westphalia 45136, Germany
    Recruiting
    • Johanna Frindte · Contact
  • Hämatologie-Onkologie im Zentrum MVZ GmbH
    Augsburg, 86150, Germany
    Recruiting
    • Dr. med. Bernhard Heinrich · Contact
  • DBZ Onkologie
    Berlin, 12623, Germany
    Recruiting
    • Dr. med. Antje Müller · Contact
  • Praxisklinik Krebsheilkunde für Frauen
    Berlin, 13597, Germany
    Recruiting
    • Gülten Oskay-Özcelik · Contact
  • Klinik für Gynäkologie und Geburtshilfe, Brustzentrum/Studiensekretariat
    Berlin, Germany
    Recruiting
    • Michael Untch, Prof. Dr. med. · Contact
  • Onkologische Schwerpunktpraxis Bielefeld
    Bielefeld, 33604, Germany
    Recruiting
    • Dr. med. Siemke Steinke · Contact
  • Klinikum Chemnitz gGmbH
    Chemnitz, Germany
    Not yet recruiting
    • Paul Gaß, Prof. Dr. med. · Contact
  • Department of Breast-Center Holweide - Kliniken der Stadt Köln
    Cologne, 51067, Germany
    Recruiting
    • Myriam Vincent · Contact
  • Städtisches Klinikum Dessau
    Dessau, 06847, Germany
    Recruiting
    • Dr. med. Hermann Voß · Contact
  • University Hospital Carl Gustav Carus
    Dresden, 01307, Germany
    Recruiting
    • Dr. med. Theresa Link · Contact
  • Gemeinschaftspraxis Haematologie Onkologie
    Dresden, Germany
    Recruiting
    • Thomas Ilmer, PD Dr. med. · Contact
  • Center for Gynecologic Oncology
    Düsseldorf, 40235, Germany
    Recruiting
    • Dr. med. Athina Kostara · Contact
  • Studienzentrale fuer das MVZ Eggenfelden e.K.
    Eggenfelden, Germany
    Not yet recruiting
    • Jürgen Terhaag, Dr. med. · Contact
  • Frauenklinik des Universitätsklinikums Erlangen
    Erlangen, 91054, Germany
    Recruiting
    • Prof. Dr. med. MD Peter Fasching · Contact
  • Universitätsklinikum Essen
    Essen, Germany
    Not yet recruiting
    • Ann-Kathrin Bittner, Prof. Dr. med. · Contact
  • Klinik für Gynäkologie und Geburtshilfe Agaplesion Markus Krankenhaus
    Frankfurt, 60431, Germany
    Recruiting
    • Prof. Dr. med. Marc Thill · Contact
  • SRH Wald-Klinikum Gera GmbH
    Gera, 07548, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Mammazentrum HH am Krankenhaus Jerusalem
    Hamburg, 20357, Germany
    Recruiting
    • Prof. Dr. med. Christian Schem · Contact
  • Klinikum Hanau
    Hanau, 63450, Germany
    Recruiting
    • Dr. med. Jens Kosse · Contact
  • DIAKOVERE Henriettenstift Frauenklinik
    Hanover, 30171, Germany
    Recruiting
    • Dr. med. Kristina Lübbe · Contact
  • National Center for Tumor Diseases - University Hospital Heidelberg
    Heidelberg, 69120, Germany
    Recruiting
    • Prof. Dr. med. Andreas Schneeweiss · Contact
  • Elisabeth Krankenhaus Brustzentrum
    Kassel, 34117, Germany
    Recruiting
    • Dr. med. Sabine Schmatloch · Contact
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
    Not yet recruiting
    • Marion van Mackelenbergh, Prof. Dr. med. · Contact
  • Praxis für Hämatologie und Onkologie Koblenz and InVo - Institut für Versorgungsforschung in der Onkologie GbR
    Koblenz, 56068, Germany
    Recruiting
    • Prof. Dr. med. Rudolf Weide · Contact
  • University Hospital Mannheim
    Mannheim, 68167, Germany
    Recruiting
    • Priv. Doz. Dr. med. Mattea Reinisch · Contact
  • University Hospital Gießen and Marburg, Campus Marburg
    Marburg, 35043, Germany
    Recruiting
    • Dr. med. Niklas Gremke · Contact
  • Media Vita GmbH (MVZ)
    Münster, 48145, Germany
    Recruiting
    • Dr. med. Stefanie Wiebe · Contact
  • St. Louise Frauen- und Kinderklinik
    Paderborn, Germany
    Recruiting
    • Michael Patrick Lux, Prof. Dr. med. · Contact
  • University Hospital Tübingen
    Tübingen, 72076, Germany
    Recruiting
    • Prof. Dr. med. Andreas Hartkopf · Contact
  • Department of Gynecology and Obstetrics - University of Ulm
    Ulm, 89075, Germany
    Recruiting
    • PhD MD Brigitte Rack · Contact
  • GRN Klinik Weinheim
    Weinheim, 69469, Germany
    Recruiting
    • Dr. med. Lelia-Eveline Bauer · Contact
  • Klinikum Worms
    Worms, 67550, Germany
    Recruiting
    • Dr. med. Sebastian Züfle · Contact
  • Helios Universitätsklinikum Wuppertal
    Wuppertal, 42283, Germany
    Recruiting
    • Assoz. Prof. Priv.Doz. Dr. med. univ et scient. med., MBAVesna Bjelic-Radisic · Contact
  • AOSS Antonio e Biagio e Cesare Arrigo
    Alessandria, Italy
    Not yet recruiting
    • Maura Vincenti, Dr. med. · Contact
  • Università Politecnica delle Marche - Azienda Ospedaliero Universitarià delle Marche
    Ancona, Italy
    Not yet recruiting
    • Prof. Rossana Berardi · Contact
  • Uo Medicina Oncologica Ospedale Di Carpi
    Carpi, Italy
    Recruiting
  • ASST Lecco Ospendale A. Manzoni
    Lecco, Italy
    Recruiting
    • Antonio Ardizzola, Dr. med. · Contact
  • AULSS9 Scaligera - Ospedale Mater Salutis di Legnago
    Legnago, 37045, Italy
    Recruiting
    • Dr. med. Anna Mercanti · Contact
  • Istituto Europeo di Oncologica
    Milan, 20141, Italy
    Recruiting
    • MD Marco Colleoni · Contact
  • Instituti Clinici Scientifici Maugeri S.p.A. SB Oncologia Medica
    Pavia, Italy
    Recruiting
    • Laura Locati, MD, PhD · Contact
  • SOC Oncologia S. Maria della Misericordia
    Udine, Italy
    Recruiting
    • Elena Poletto · Contact
  • Ospedale di Circolo e Fondazione Macchi
    Varese, Italy
    Not yet recruiting
    • Elisa Gallerani, Dr. med. · Contact
  • Narodowy Instytut Onkologii
    Warsaw, Poland
    Not yet recruiting
    • Zbigniew Nowecki, Prof. Dr. med. · Contact
  • Spitalul Clinic Filantropia
    Bucharest, Romania
    Recruiting
    • Dragos Median · ContactDr. med.
  • Institutul Oncologic "Prof. Dr. Ion Chiricuta"
    Cluj-Napoca, Romania
    Recruiting
    • Nicoleta Antone, Dr. med. · Contact
  • Institutul Regional de Oncologie Iasi
    Iași, Romania
    Recruiting
    • Simona Volovat, Dr. med. · Contact
  • Centrul ONCOMED SRI
    Timișoara, Romania
    Recruiting
    • Cristina Oprean, Dr. med. · Contact
  • Narodny onkologicky ustav
    Bratislava, Slovakia
    Recruiting
    • Michal Mego · Contact
  • Hospital Clinic of Barcelona Medical Oncology
    Barcelona, Spain
    Recruiting
    • Francesco Schettini, MD, PhD · Contact
  • Hospital Universitari Vall d´Hebron
    Barcelona, Spain
    Recruiting
    • Santiago Escrivá de Romani Munoz, Dr. med. · Contact
  • Institut Catalá dÒncologia (ICO)
    Barcelona, Spain
    Recruiting
    • Sonia Pernas Simon, Dr. med. · Contact
  • Hospital Universitario Clinico San Cecilio Oncology
    Granada, Spain
    Recruiting
    • Isabel Blancas, Dr. med. · Contact
  • Fundació IRB Lleida Oncología, Unidad de ensayos clínicos
    Lleida, Spain
    Recruiting
    • Serafin Morales, Dr. med. · Contact
  • Hospital de Madrid Notre Sanchinarro (CIOCC)
    Madrid, Spain
    Recruiting
    • Ana Luna Barrera · Contact
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
    Recruiting
    • Rodrigo Sanchez Bayona, Dr. med. · Contact
  • Hospital Universitario Ramon y Cajal Servicio de Oncología Médica/ Oficina de Ensayos Clínicos
    Madrid, Spain
    Recruiting
    • Elena Lopez Miranda · Contact
  • Hospital General Universitario Morales Meseguer
    Murcia, Spain
    Recruiting
    • Elisa Garcia Garre, MD PhD · Contact
  • Hospital Universitario Son Espases
    Palma de Mallorca, Spain
    Recruiting
    • Nieves Ferrer Tur, Dr, med. · Contact
  • Hospital Universitario Marquès de Valdecilla Servicio de Oncologia Medica
    Santander, Spain
    Recruiting
    • Carmen Hinojo Gonzalez, Dr. med. · Contact
  • Hospital Universitario Virgen der Rocio
    Seville, Spain
    Recruiting
    • Javier Salvador · ContactDr. med.
  • Fundación Instituto Valenciano de Oncología (IVO)
    Valencia, Spain
    Recruiting
    • Cristina Hernando Meliá, Dr. med. · Contact
  • Hospital Clínico Universitario de Valencia
    Valencia, Spain
    Recruiting
    • Juan Miguel Cejalvo, Dr. med. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 48 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Mar 31, 2022
StartActual
Jan 2, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05306041
Lead sponsor
GBG Forschungs GmbH
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Jan 2, 2023
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Jana Roßney
Contact
geparpippa@gbg.de
+49(0)6102 7480 ext. 292
Mattea Reinisch, PD Dr. med.
principal investigator · Universitätsmedizin Mannheim, Frauenklinik mit Brustzentrum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion